Document:

EX-4.3

 Exhibit 4.3 

DATE: 6 DECEMBER 2019 
  

 
 DEED OF TERMINATION OF A
RELATIONSHIP AGREEMENT 
 DATED 14 DECEMBER 2018 
  

 
 Between 

SUMMIT THERAPEUTICS PLC 

ROBERT W. DUGGAN 
 and 

CAIRN FINANCIAL ADVISERS LLP 
  

 
 CMS Cameron McKenna Nabarro Olswang LLP

 Cannon Place 
 78 Cannon Street

 London EC4N 6AF 
 T +44 20 7367
3000 
 F +44 20 7367 2000 

cms.law 

 TABLE OF CONTENTS 

 

							
	 1.
	 	Definitions and Interpretation	  	 	1	 
	 2.
	 	Condition	  	 	1	 
	 3.
	 	Mutual release and waiver of rights	  	 	2	 
	 4.
	 	Miscellaneous	  	 	2	 

 THIS DEED is made on 6 December 2019 

BETWEEN: 
  

	(1)	 SUMMIT THERAPEUTICS PLC (incorporated and registered in England and Wales under registration number
05197494), the registered office of which is at 136a Eastern Avenue, Milton Park, Abingdon, Oxfordshire OX14 4SB, United Kingdom (the “Company”); 

 

	(2)	 ROBERT W. DUGGAN, of 611 South Fort Harrison Avenue, Suite 306, Clearwater, Florida 33756, United States
(the “Investor”); and 

  

	(3)	 CAIRN FINANCIAL ADVISERS LLP (incorporated and registered in England and Wales under registration number
OC351689), the registered office of which is at Cheyne House, Crown Court, 62-63 Cheapside, London EC2V 6AX, United Kingdom (the “Nomad”). 

RECITALS 
  

	(A)	 The Company, the Investor and the Nomad entered into a relationship agreement dated 14 December 2018,
relating to the Investor’s shareholding in the Company (the “Relationship Agreement”). 

  

	(B)	 Each of the parties has agreed to enter into this deed in order, subject to satisfaction of the Condition (as
defined below), to terminate the continuing provisions of the Relationship Agreement and waive any past breaches of it. 

 Operative
Provisions 
  

	1.	 DEFINITIONS AND INTERPRETATION 

 

	1.1	 In this deed: 

  

	 	1.1.1	 “AIM Delisting” means the proposed cancellation of the Company’s ordinary shares
of £0.01 each from admission to trading on the AIM market of the LSE. 

  

	 	1.1.2	 “LSE” means the London Stock Exchange Plc. 

 

	 	1.1.3	 The headings and sub-headings are for convenience only and shall not
affect the construction of this deed. 

  

	 	1.1.4	 References to “the parties” or to a “party” are to parties (or a party) to
this deed and include the parties’ successors. 

  

	 	1.1.5	 Unless the context otherwise requires, words denoting the singular shall include the plural and vice versa and
references to any gender shall include all other genders. 

  

	2.	 CONDITION 

  

	2.1	 The provisions of this deed shall be conditional on, and shall take effect upon, the AIM Delisting becoming
effective by way of the issue by the LSE of a dealing notice (as such term is defined in the AIM Rules for Companies) (the “Condition”). 

  

	2.2	 If satisfaction of the Condition has not taken place on or before 30 April 2020 this deed shall lapse and
the Relationship Agreement shall continue to have full force and effect. 

  
 1 

	3.	 MUTUAL RELEASE AND WAIVER OF RIGHTS 

 

	3.1	 With effect from the satisfaction of the Condition, each of the parties: 

 

	 	3.1.1	 agrees that each of the other parties shall be released from all of its continuing obligations (if any) under
the Relationship Agreement, to the intent that with effect from that time the Relationship Agreement shall be terminated and be of no further force or effect; and 

 

	 	3.1.2	 except in the case of fraud, irrevocably waives and releases all rights it presently has or which, in the
absence of this deed, it might otherwise have had to bring a claim against any one or more of the other parties pursuant to, or in respect of the subject matter of, the Relationship Agreement, whether in relation to past, present or future
circumstances, and regardless of whether it presently knows or could know of the grounds or legal basis for any such claim. 

  

	4.	 MISCELLANEOUS 

 

	4.1	 This deed may be executed in counterparts and by the parties on different counterparts. Each counterpart shall
constitute an original of this deed but all the counterparts shall together constitute one and the same deed. 

  

	4.2	 Nothing in this deed is intended to confer on any person any right to enforce any term of this deed which that
person would not have had but for the Contracts (Rights of Third Parties) Act 1999. 

  

	4.3	 Each party shall bear its own costs and expenses in relation to the negotiation, preparation, execution and
carrying into effect of this deed. 

  

	4.4	 This deed, and any non-contractual rights or obligations arising out of
or in connection with it or its subject matter, shall be governed by and construed in accordance with English law and each of the parties agrees that the courts of England shall have exclusive jurisdiction to settle any dispute which may arise out
of or in connection with this deed or its subject matter 

 IN WITNESS of which the parties have signed this instrument as a deed
and have delivered it upon dating it. 
  

					
	Executed as a deed by	  	)	  	
	SUMMIT THEREPEUTICS PLC	  	)	  	
	on being signed by	  	)	  	/s/ Glyn Edwards
	/s/ Glyn Edwards	  	)	  	Director
	in the presence of:	  	)	  	

  

			
	Signature of witness:	 	 /s/ Melissa Strange

	Name:	 	Melissa Strange
		
	Address:	 	                                      
              
		
		 	                                      
              
		
	Occupation:	 	Accountant

  
 2 

					
	Signed as a deed by	  	)	  	
	ROBERT W. DUGGAN	  	)	  	/s/ Robert W. Duggan
	in the presence of:	  	)	  	

  

			
	Name of witness:	  	Catherine Zwan
		
	Signature of witness:	  	/s/ Catherine Zwan
		
	Address:	  	                                      
              
		
		  	                                      
              
		
	Occupation:	  	Executive Assistant

  

					
	Executed as a deed by	  	)	  	
	CAIRN FINANCIAL ADVISERS LLP	  	)	  	/s/ Anthony Rawlinson
	acting by	  	)	  	Member
	Anthony Rawlinson	  	)	  	
	and	  	)	  	
	Liam Murray	  	)	  	/s/ Liam Murray
	each a member, in the presence of:	  	)	  	Member

  

			
	Signature of witness:	  	/s/ Ludovico Christopher Lazzaretti
	Name:	  	Ludovico Christopher Lazzaretti
	Address:	  	                                      
              
		  	                                      
              
	Occupation:	  	Executive

  
 3EX-4.4

 Exhibit 4.4 

CONSULTING AGREEMENT 

This Consulting Agreement (the “Agreement”) dated December 6, 2019 is entered into by and between Summit Therapeutics
plc, a public limited company incorporated in England and Wales with the Registrar of Companies of England and Wales (the “Company”), having a principal place of business at 136a Eastern Avenue, Milton Park, Abingdon, Oxfordshire,
OX14 4SB, United Kingdom, and Maky Zanganeh & Associates, Inc., a California corporation (“Consultant”), having a business address at 2882 Sand Hill Rd., Suite 106, Menlo Park, California 94025, United States of America.
The Company and Consultant are each a “Party” hereunder and collectively “the Parties.” The Agreement will be effective upon the date of Admission (as such term is defined in the Company’s circular to shareholders dated on
or around the date of this Agreement in connection with a proposed equity investment in the Company by Robert Duggan) (the “Effective Date”). 

1. Consulting Relationship. During the Consultation Period (as defined below), Consultant shall provide consulting services to the
Company as described on Exhibit A to this Agreement (the “Services”), including through Consultant’s Assistant(s) (as defined below). Assistants are direct employees of Consultant. Assistant(s) shall have qualifications,
experience and ability to properly perform the Services on behalf of Consultant. Consultant will use commercially reasonable efforts to perform the Services. The Company shall provide access to its information and property as may be reasonably
required in order to permit Consultant to perform its obligations hereunder. Consultant shall cooperate with the Company’s personnel and shall not interfere with the conduct of the Company’s business. In performing the Services, Consultant
will comply with all business conduct, regulatory and health and safety laws or regulations established by any governmental authority and all such guidelines established by the Company of which Consultant has been advised of in writing with respect
to the business of the Company and shall indemnify, defend and hold harmless the Company and its successors and assigns from any claims, suits, judgments or causes of action initiated by any third party against the Company where such actions result
directly from the Services performed by the Consultant or its Assistants in violation of or conflict with any such laws, guidelines or regulations. Notwithstanding the foregoing, Consultant will not indemnify for any claims brought by or on
behalf of patients participating in the Phase 3 clinical trials of Ridinilazole. The Parties hereby agree that the selection of the Assistants will be by Consultant. The Services will be performed at Consultant’s facilities unless the Company
has a specific need for Consultant to travel for a business meeting and Consultant is available to travel at such time. Company will provide adequate notification if such travel is required. 

2. Fees. As consideration for the Services to be provided by Consultant, the Company shall pay or cause to be paid to
Consultant the compensation as specified in Exhibit B attached to this Agreement at the times specified therein. It will be Consultant’s sole obligation to report all compensation for Services received by Consultant from Company to the
appropriate federal, state and local tax authorities as applicable. For the avoidance of doubt, the Parties agree that on and as of the Effective Date, no additional fees shall be payable to Consultant pursuant to that certain Consulting Agreement,
dated as of October 16, 2019, by and between the Parties (the “Consulting Agreement”) other than fees earned prior to the Effective Date of this Agreement. 

 3. Expenses. Consultant and its Assistants and Subcontractors (as
defined below) shall not be authorized to incur any expenses on behalf of the Company. Notwithstanding the foregoing, the Company shall reimburse Consultant for all reasonable, documented and authorized travel and out-of-pocket expenses, incurred or paid by Consultant and its Subcontractors in connection with, or related to, the performance of Services under this Agreement with the prior written approval of the
Company. Consultant and any Assistant or Subcontractor agrees to comply with the Company’s expense reimbursement policy regarding travel, lodging and meals attached as Exhibit C. Any requests for approval shall be responded to within
twenty-four (24) hours of the request to minimize the cost of last minute bookings and allow for appropriate planning. As a condition to receipt of reimbursement, Consultant shall be required to submit to the Company reasonable evidence that
the amount involved was expended and related to Services provided under this Agreement. Consultant shall bill the Company for expenses within fifteen (15) days of the last day of the calendar month, and the Company shall reimburse Consultant
directly within 30 days of submission of such invoice. 
 4. Term and Termination. Consultant shall serve as a
consultant to the Company for a period commencing on the Effective Date and terminating on the three (3) year anniversary of the Effective Date (the “Consultation Period”). 

Consultant may terminate this Agreement upon fifteen (15) days prior notice. 

5. Intellectual Property and Return of Company Information 

5.1 Intellectual Property 

5.1.1 All inventions, ideas, creations, discoveries, computer programs, works of authorship, data, developments, technology, designs,
innovations and improvements (whether or not patentable and whether or not copyrightable) which are made, conceived, reduced to practice, created, written, designed or developed by Consultant, solely or jointly with others or under its direction and
whether during normal business hours or otherwise, (i) during the Consultation Period if directly related to the business of the Company as to clostridium difficile antibiotics and the Services or (ii) after the Consultation Period if
resulting or directly derived from Proprietary Information (as defined below) (collectively under clauses (i) and (ii), “Inventions”), shall be the sole property of the Company. Consultant hereby assigns to the Company all
Inventions and any and all related patents, copyrights, trademarks, trade names, and other industrial and intellectual property rights and applications therefor, in the United States and elsewhere to the maximum extent permitted by Section 2870
of the California Labor Code or any like statute of any other state. Consultant understands that the provisions of this Agreement requiring assignment of Inventions to the Company do not apply to any Invention which qualifies fully under the
provisions of California Labor Code Section 2870 (attached hereto as Exhibit D). Consultant also appoints any officer of the Company as its duly authorized attorney to execute, file, prosecute and protect the same before any government
agency, court or authority. 
 5.1.2 Upon the request of the Company and at the Company’s expense, Consultant shall execute such
further assignments, documents and other instruments as may be necessary or desirable to fully and completely assign all Inventions to the Company and to assist the Company in applying for, obtaining and enforcing patents or copyrights or other
rights in the United States and in any 

  
 2 

 
foreign country with respect to any Invention. Consultant also hereby waives all claims to moral rights in any Inventions. Without limiting the generality of the foregoing, the Company will have
the unrestricted right to use, reproduce, modify, distribute, display and make derivative works of all writings, documents and results generated under or otherwise resulting from this Agreement, whether in written, graphic, electronic or other
media. 
 5.1.3 Consultant shall promptly disclose to the Company all Inventions and will maintain adequate and current written records (in
the form of notes, sketches, drawings and as may be specified by the Company) to document the conception and/or first actual reduction to practice of any Invention. Such written records shall be available to and remain the sole property of the
Company at all times. 
 5.1.4 For clarity purposes, the Parties agree that Inventions will not include, and the provisions of this
Agreement requiring assignment of Inventions to the Company do not apply to any inventions that are developed outside of the Services and are not directly derived from Proprietary Information of the Company. 

5.2 Infringing Actions. Consultant will not knowingly infringe upon any copyright, patent, trade secret or
other property right of any former client, employer or third party in the performance of the Services required by this Agreement. 
 5.3
Return of Company Information. Upon termination of this Agreement or at any other time upon request by the Company, Consultant shall promptly deliver to the Company or destroy all records, files, memoranda, notes, designs, data,
reports, price lists, customer lists, drawings, plans, computer programs, software, software documentation, sketches, laboratory and research notebooks and other documents (and all copies or reproductions of such materials) containing Proprietary
Information, whether created by Consultant or others, which shall come into its custody or possession at the expense of the Company. If documents are to be destroyed, Consultant agrees to certify that all such documents have been destroyed.
Consultant may retain copies of Proprietary Information that are stored on Consultant’s IT backup and disaster recovery systems until the ordinary course deletion thereof. Consultant shall continue to be bound by the terms and conditions of
this Agreement with respect to such retained Proprietary Information. 
 6. Independent Contractor. Consultant
represents and warrants to the Company that it is an “independent contractor” as defined under U.S. Treasury Regulation Section 1.409A-1(f)(2). Consultant and its Assistants shall perform all
Services under this Agreement as an independent contractor acting in the ordinary course of its business. Consultant and its Assistants are not Company employees. Consultant and its Assistants are not authorized to assume or create any obligation or
responsibility, express or implied, on behalf of, or in the name of, the Company or to bind the Company in any manner. 
 (a) Method of
Provision of Services: Except as otherwise expressly provided in this Agreement, Consultant shall be solely responsible for determining the method, details and means of performing the Services. Subject to Section 1, Consultant
may select such employees of Consultant as Consultant deems necessary to perform the Services required by this Agreement (the “Assistants”). Consultant shall be wholly responsible for the professional performance of the Services by
its Assistants. 

  
 3 

 
Consultant shall expressly advise the Assistants of the terms of this Agreement and shall require each Assistant to abide by the confidentiality requirements of this Agreement. Consultant may
recommend that the Company engage with third party contractors, subcontractors and/or consultants (hereinafter referred to as “Subcontractors”). The use of such Subcontractors shall be approved in advance and in writing by the
Company, such approval not to be unreasonably withheld. Consultant shall pay for the fees of the Subcontractors. However, Company agrees to reimburse all such fees for the Subcontractors, within thirty (30) days of receipt of an invoice for
such fees. Consultant and/or its Assistants will review and oversee work done by Subcontractors. In the event that the Company permits Consultant to use the services of one or more Subcontractors, Consultant shall be liable for any breach of the
provisions of this Agreement by its Subcontractors. In no event shall Consultant, or any Assistant, Subcontractor, partner, agent, employee of Consultant, perform any portion of the Services outside the United States of America, except upon the
request or with the prior approval of the Company. 
 (b) No Authority to Bind Company. Neither Consultant, nor any
Assistant, Subcontractor, partner, agent, employee of Consultant shall have or purport to have authority to enter into contracts that bind the Company, or create obligations on the part of the Company without the prior written authorization of the
Company’s Chief Executive Officer (“CEO”), Chief Operating Officer (“COO”) or CEO/COO designee. 
 (c)
No Benefits. Consultant acknowledges and agrees that Consultant and its Assistant(s) will not be eligible for any Company employee benefits, including, without limitation, social security, unemployment, medical or pension
payments made available to employees of the Company, and, to the extent Consultant or its Assistant(s) otherwise would be eligible for any Company employee benefits but for the express terms of this Agreement, Consultant (on behalf of itself and its
employees) hereby expressly declines to participate in such Company employee benefits. 
 (d) Taxes; Indemnification.
Consultant shall have full responsibility for any amount of taxes, duties and social security contributions (including interest and penalties) with regard to all compensation paid to Consultant (including for any of its Assistants) under this
Agreement, in each case imposed (i) by the United States or any subdivision thereof or (ii) to the extent such amount becomes due other than by reason of an action taken by Consultant pursuant to this Agreement that was previously
requested or approved by the Company, any other taxing jurisdiction. For purposes of clarity, the Services described in Exhibit A have been requested and approved by the Company. Consultant will comply with all applicable labor and employment
requirements with respect to Services hereunder. Consultant shall be responsible for its form of business organization and operations, including state worker’s compensation insurance coverage requirements and any US immigration visa
requirements. Consultant agrees to indemnify, defend and hold the Company harmless from any liability for, or assessment of, any claims or penalties from third parties (including governmental authorities) with respect to any U.S. tax, labor or
employment requirements relating to Services or payments hereunder. 
 (e) Tax Information. As a condition to payment under
this Agreement, upon its execution hereof Consultant shall provide a complete and accurate IRS Form W-9 to the Company. 

  
 4 

 7. Supervision of Consultant’s Services. All of the Services to be performed by
Consultant, will be as agreed between Consultant and the Company’s CEO, COO or CEO/COO designee and attached hereto as Exhibit A. From time to time, the Parties may agree to amend Exhibit A; such amendment shall be in writing and
signed by a duly authorized designee of each Parties. Upon execution of both Parties, the revised or amended Exhibit A shall be part of this Agreement. 

8. Consulting or Other Services for Competitors. Consultant represents and warrants that Consultant and its Assistant(s) do not
presently perform nor intend to perform, during the Consultation Period, consulting services for companies whose businesses are to develop antibiotics or other therapeutics for clostridium difficile infection. Nothing in this Agreement is intended
to preclude Consultant or its Assistants from investing financially in competitors of the Company, even if such competitor’s products or services directly compete with the Company’s products or services, or from consulting for companies
that are not direct competitors of the Company. 
 9. Confidentiality. Consultant agrees that all information, whether or not in
writing, concerning the Company’s business, technology, business relationships or financial affairs which the Company has not released to the general public (collectively, “Proprietary Information”) is and will be the exclusive
property of the Company. By way of illustration, but not limitation, Proprietary Information may include information or material which has not been made generally available to the public, such as: (a) corporate information, including
plans, strategies, methods, policies, resolutions, negotiations or litigation; (b) marketing information, including strategies, methods, customer identities or other information about customers, prospect identities or other information
about prospects, or market analyses or projections; (c) financial information, including cost and performance data, debt arrangements, equity structure, investors and holdings, purchasing and sales data and price lists;
(d) operational and technological information, including plans, specifications, manuals, forms, templates, pre-clinical and clinical testing data and strategies, software, designs, methods,
procedures, formulas, discoveries, inventions, improvements, concepts and ideas; and (e) personnel information, including personnel lists, reporting or organizational structure, resumes, personnel data, compensation structure,
performance evaluations and termination arrangements or documents. Proprietary Information also includes information received in confidence by the Company from its customers, clients, or suppliers or other third parties. Consultant will not, at any
time, without the Company’s prior written permission, either during or after the Consultation Period, disclose any Proprietary Information to anyone outside of the Company, or use or permit to be used any Proprietary Information for any purpose
other than the performance of its duties as a Consultant of the Company. Consultant will cooperate with the Company and use its best efforts to prevent the unauthorized disclosure of all Proprietary Information. Consultant will deliver to the
Company all copies of Proprietary Information in its possession or control upon the earlier of a request by the Company or termination of this Agreement. Consultant understands that the Company is now and may hereafter be subject to non-disclosure or confidentiality agreements with third parties, which require the Company to protect or refrain from use of proprietary or the confidential information of the third party. Consultant agrees to be
bound by the terms of such agreements in the event Consultant has access to such proprietary or confidential information. Consultant’s obligations under this Section 9 shall not apply to any information that (i) is or becomes known to
the general public under circumstances involving no breach by Consultant or others of the terms of this Section 9, (ii) is generally disclosed to third parties by the Company without restriction on such third parties, or (iii) is
approved for release by written authorization of an officer of the Company. Consultant warrants that each of the individuals in Consultant’s employ or participating in the rendering of the Services under its supervision, including its
Assistant(s) and any Subcontractors, is bound by a confidentiality agreement with terms at least as stringent as the terms of this Section 9 that Consultant has signed with the Company. Notwithstanding the foregoing, Consultant shall remain
liable for any breach by its Assistants or any Subcontractors of any confidentiality obligation herein. 

  
 5 

 10. Conflicts with this Agreement. Consultant represents and warrants that neither
Consultant nor its Assistant(s) currently have any agreement with, nor any other obligation to, any third party that would conflict with the terms of this Agreement, nor shall Consultant enter into any such agreement nor incur such an obligation,
without the prior written consent of the Company. Consultant further represents that the performance of the Services will not breach any agreement or obligation with any third party, including without limitation any obligation to refrain from
engaging in activities that may compete with such party. 
 11. U.S. Securities Laws. Consultant hereby acknowledges that
Consultant is aware, and further agrees that Consultant will advise those of its directors, officers, employees, agents, Assistants and Subcontractors who may have access to confidential information about the Company, that United States securities
laws prohibit any person who has material, non-public information about a company from purchasing or selling securities of such a company or from communicating such information to any other person under
circumstances in which it is reasonably foreseeable that such person is likely to purchase or sell such securities. 
 12. Solicitation
of Employees, Consultants and Other Parties. The Company and Consultant agree that during the Consultation Period, and for a period of twenty-four (24) months immediately following the termination of the Agreement for any reason,
whether with or without cause, neither Party shall either directly or indirectly solicit, induce, recruit or encourage any of the other Parties’ employees or consultants to terminate their relationship with the other Party, or attempt to
solicit, induce, recruit, encourage or take away employees or consultants of the other Party, either for itself or for any other person or entity. Further, during the Consultation Period and at any time following the termination of the Agreement for
any reason, whether with or without cause, Consultant shall not use any Proprietary Information of the Company to negatively influence any of the Company’s clients or customers from purchasing Company products or services or to solicit or
influence or attempt to influence any client, customer or other person either directly or indirectly, to direct any purchase of products and/or services to any person, firm, corporation, institution or other entity in direct competition with the
Company as defined herein. 
 13. Force Majeure. Neither Party shall lose any rights hereunder or be liable to the other
Party for damages or losses on account of failure of performance by the defaulting Party, other than a failure to make payment, if the failure is occasioned by government action, war, terrorism, fire, explosion, flood, strike, lockout, embargo,
shortage of materials or utilities, vendor failure to supply, act of God, or any other cause beyond the control and without the fault or negligence of the defaulting Party, provided that the Party claiming force majeure has exerted all reasonable
efforts to avoid or remedy such force majeure; provided, however, that in no event shall a Party be required to settle any labor dispute or disturbance. Such excuse shall continue as long as the condition preventing the performance continues. Upon
cessation of such condition, the affected Party shall promptly resume performance hereunder. Each Party agrees to give the other Party prompt written notice of the occurrence of any such condition, the nature thereof, and the extent to which the
affected Party will be unable to perform its obligations hereunder. Each Party further agrees to use all reasonable efforts to correct the condition as quickly as possible and to give the other Party prompt written notice when it is again fully able
to perform its obligations hereunder. 

  
 6 

 14. Assignment. Neither Party may assign this Agreement without
prior written consent from the other Party. This Agreement will be binding upon and inure to the successors and permitted assignees of the Parties and the name of a Party appearing herein will be deemed to include the names of such Party’s
successor’s and permitted assigns to the extent necessary to carry out the intent of this Agreement. Any assignment not in accordance with this Section 14 will be null and void. 

15. Miscellaneous. 

(a) Amendments and Waivers. This Agreement may be amended or modified only by a written instrument executed by both the
Company and Consultant. 
 (b) Entire Agreement. This Agreement, including the Exhibits hereto, constitutes the entire
agreement between the parties and supersedes all prior agreements and understandings, whether written or oral, relating to the subject matter of this Agreement, including the Consulting Agreement. 

(c) Notices. Any notice required or permitted by this Agreement shall be in writing and shall be deemed sufficient upon
receipt, when delivered personally or by courier, overnight delivery service or confirmed facsimile, 48 hours after being deposited in the regular mail as certified or registered mail (airmail if sent internationally) with postage prepaid, if such
notice is addressed to the Party to be notified at such Party’s address or facsimile number as set forth above, or as subsequently modified by written notice. 

(d) Choice of Law. The validity, interpretation, construction and performance of this Agreement shall be governed by the
laws of the State of California, without giving effect to the principles of conflict of laws. 
 (e) Severability. If
any term, provision, covenant or condition set forth herein (including, without limitation, the exhibits hereto) or the application thereof to any circumstance shall, in any jurisdiction and to any extent, be invalid, void or unenforceable, such
term or provision shall be ineffective as to such jurisdiction to the extent of such invalidity or unenforceability without invalidating or rendering unenforceable the remaining terms, provisions, covenants or conditions hereof or the application of
such terms, provisions, covenants or conditions to circumstances other than those as to which it is held invalid or unenforceable, and a suitable and equitable term or provision shall be substituted therefor to carry out, insofar as may be valid and
enforceable, the intent and purpose of the invalid or unenforceable term, provision, covenant or condition. 
 (f)
Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together will constitute one and the same instrument. Each Party agrees that the delivery of the signed
Agreement by facsimile or in electronically readable format shall have the same force and effect as delivery of original signature and that each Party may use such signatures as evidence of the execution and delivery of the Agreement by all Parties
to the same extent that an original signature could be used. 

  
 7 

 (g) Advice of Counsel. EACH PARTY ACKNOWLEDGES THAT, IN EXECUTING THIS
AGREEMENT, SUCH PARTY HAS HAD THE OPPORTUNITY TO SEEK THE ADVICE OF INDEPENDENT LEGAL COUNSEL, AND HAS READ AND UNDERSTOOD ALL OF THE TERMS AND PROVISIONS OF THIS AGREEMENT. THIS AGREEMENT SHALL NOT BE CONSTRUED AGAINST ANY PARTY BY REASON OF THE
DRAFTING OR PREPARATION HEREOF. 
 [Signature Page Follows] 

  
 8 

 The Parties have executed this Agreement on the respective dates set forth below. 

 

			
	SUMMIT THERAPEUTICS PLC
		
	By:	 	 /s/ Glyn Edwards

		 	Glyn Edwards, Chief Executive Officer
		
	Date:	 	December 6, 2019
	
	MAKY ZANGANEH & ASSOCIATES, INC.
		
	By:	 	 /s/ Mahkam Zanganeh

	Name:	 	Mahkam Zanganeh
	Title:	 	CEO
	Address:	 	2882 Sand Hill Road, Suite 106
		 	Menlo Park, CA 94025

  
 9 

 EXHIBIT A 

DESCRIPTION OF CONSULTING SERVICES 

Description of Services 
 Services will
include the following: 
  

	 	1.	 Evaluation of and assistance in managing the contract research organization responsible for the Phase 3
clinical trials of Ridinilazole in clostridium difficile infection. 

  

	 	2.	 Assistance with site management and support for the Phase 3 clinical trials of Ridinilazole in clostridium
difficile infection. 

  

	 	3.	 Assistance with acceleration of patient enrollment for the Phase 3 clinical trials of Ridinilazole in
clostridium difficile infection. 

  

	 	4.	 Assistance with FDA filing of the NDA for Ridinilazole (including organization, drafting, editing &
review of documents). 

  

	 	5.	 Provide detailed development strategy plan for the clinical and regulatory programs for Ridinilazole in
clostridium difficile infection. 

  
 10 

 EXHIBIT B 

COMPENSATION 
 Consultant shall be granted
a warrant to acquire 16,793,660 ordinary shares of the Company (the “Warrant”). The Warrant shall have an exercise price per share equivalent to £0.221. The Warrant shall vest in equal quarterly installments over three years,
subject to the provision of on-going Services to the Company by Consultant during the Consultation Period. Consultant shall have five (5) years from the termination or expiration date of this Agreement or
ten (10) years from the date of grant of the Warrant, whichever is earlier, to exercise the vested portion of the Warrant. In the event of an early termination of this Agreement by Consultant, any portion of the Warrant that is unvested as of
the time of such termination shall be forfeited immediately and automatically to the Company, without the payment of any consideration to Consultant. 
 The
Company will pay Consultant a fee of seventy-five thousand U.S. dollars ($75,000) per month during the Consultation Period, which shall be payable on the first business day of each month. The Parties may agree to increase this fee if the Company
requests that Consultant use more Assistants to support the Services than the Parties contemplated upon the date of the Agreement.  

  
 11 

 EXHIBIT C 

EXPENSE REIMBURSEMENT POLICY 

  
 12 

 EXHIBIT D 

CALIFORNIA LABOR CODE SECTION 2870 

INVENTION ON OWN TIME – EXEMPTION FROM AGREEMENT 

  
 13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00302-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00302-of-00352.parquet"}]]